Our findings reveal critical mechanisms by which CLL cells exploit the TME to drive pathogenesis and therapeutic resistance using realistic 3D setups, highlighting the potential of targeting AP‐1 and the stromal compartment in future treatment strategies. The gene discussed is JUN; the disease is B-cell chronic lymphocytic leukemia.